Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE: A) will showcase cancer research solutions at the AACR Annual Meeting in San Diego, April 17–22, 2026. Highlights include the new BioTek Cytation 9, an AI-enabled preview for xCELLigence RTCA eSight, SureSelect compatibility with Oxford Nanopore long-read sequencing, and user events.
Agilent will exhibit at booth 4527 and continue support for early-career researchers via AACR Foundation initiatives.
Agilent (NYSE: A) on April 1, 2026 announced the BioTek Cytation 9, a new cell imaging multimode reader combining multimode microplate detection with high-content imaging in one platform.
Cytation 9 adds inverted fluorescence and upright imaging optics, a multimode reader module, and claims twice the imaging speed, targeting higher-throughput cell‑based and biochemical workflows for research and drug discovery.
TORM plc (NASDAQ: TRMD A) increased share capital by 43,697 A-shares following exercise of Restricted Share Units on March 31, 2026. 10,634 shares were subscribed at DKK 131.80 and 33,063 at DKK 148.70. Post-issue share capital is USD 1,021,233.39 across 102,123,339 A-shares.
New shares are ordinary, carry dividend and voting rights from issuance, and are expected to list on Nasdaq Copenhagen as soon as possible.
Agilent (NYSE: A) announced FDA approval on March 26, 2026 for PD-L1 IHC 22C3 pharmDx, Code SK006 as a companion diagnostic to identify esophageal or gastroesophageal junction (GEJ) carcinoma patients with PD-L1 CPS ≥ 1 who may be eligible for treatment with KEYTRUDA.
This marks the eighth FDA companion diagnostic indication for 22C3. Agilent reported $6.95 billion revenue for fiscal 2025 and ~18,000 employees.
Agilent (NYSE: A) will present advances in precision oncology and digital pathology at USCAP 2026, March 21-26 in San Antonio.
Highlights include a new PD-L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), expanded biomarker testing, and integrated end-to-end digital pathology workflows built around the Dako Omnis family.
TORM plc (NASDAQ: TRMD / TRMD A) increased its share capital by 106,468 A-shares following exercise of Restricted Share Units (RSUs), corresponding to a nominal value of USD 1,064.68. A total of 34,880 shares were subscribed at DKK 131.80 and 71,588 at DKK 148.70.
The new ordinary A-shares carry voting and dividend rights as of issuance, are negotiable instruments, and are expected to be listed on Nasdaq Copenhagen as soon as possible. Transfer restrictions may apply in some jurisdictions, including U.S. securities law. After the increase, share capital totals USD 1,019,306.41 divided into 101,930,641 A-shares.
Agilent (NYSE: A) launched Agilent Advanced Therapeutics, a unified CDMO solution integrating BIOVECTRA (Canada) and Nucleic Acid Solutions (Colorado) to provide end-to-end development and manufacturing across discovery, process development, and clinical- and commercial-scale production.
The CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development, intended to streamline customer access to scalable, customizable manufacturing under a single partner.
Agilent (NYSE: A) has agreed to acquire Biocare Medical for $950 million in an all-cash transaction, adding a complementary portfolio of IHC, ISH and FISH antibodies, reagents and instruments.
Biocare generated over $90 million revenue in 2025, posted annual double-digit revenue and profit growth since 2021, and the deal is expected to be accretive to Agilent’s top-line growth, margin profile and non-instrument revenue mix in Year 1, with EPS accretion ~12 months after close. Closing is subject to regulatory approvals and expected by Agilent’s Q4 FY2026.
Agilent (NYSE: A) reported Q1 FY2026 revenue of $1.80 billion, up 7.0% reported and 4.4% core year-over-year, with GAAP EPS of $1.07 and non-GAAP EPS of $1.36. The company raised FY26 revenue guidance to $7.3–$7.5 billion and increased non-GAAP EPS range to $5.90–$6.04.
Segments: LDG revenue $679M (16.0% margin), ACG $758M (31.6% margin), AMG $361M (25.8% margin). Q2 revenue guide is $1.79–$1.82 billion; Q2 non-GAAP EPS $1.39–$1.42. Management cited weather headwinds but reaffirmed core growth and margin expansion.
Agilent (NYSE: A) will participate in TD Cowen’s 46th Annual Health Care Conference with a fireside chat featuring CFO Adam Elinoff and Head of Investor Relations Tejas Savant on March 3, 2026, 11:10–11:40 a.m. EST in Boston.
A live audio webcast and replay will be available on Agilent’s Investor Relations website. Agilent reported $6.95 billion revenue for fiscal 2025 and employs approximately 18,000 people worldwide.